Login / Signup

Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.

Xavier RoblinG BoschettiN WillietS NanceyH MarotteA BergerJ M PhelipL Peyrin-BirouletJean Frederic ColombelE Del TedescoS PaulB Flourie
Published in: Alimentary pharmacology & therapeutics (2017)
Under combination therapy, AZA dose reduction, but not withdrawal, appears to be as effective as continuation of AZA at full dose.
Keyphrases
  • combination therapy
  • clinical trial
  • end stage renal disease
  • open label
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • study protocol
  • double blind
  • phase ii
  • patient reported